Lappe Mark: insider trades.
Lappe Mark reported 10 non-derivative transactions on 2 SEC ownership filings in Q3 2026: 10 open-market purchases ($3.6M) and 0 sales, across 1 company.
- Transactions
- 10
- Purchases (P)
- 10
- Sales (S)
- 0
- Companies
- 1
- Name as filed
- Lappe Mark
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | Director, Officer · Chief Executive Officer | 10 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-28 | Inhibrx Biosciences, Inc. | P | 1,500 | $98.88 | 737,548 | Form 4 |
| 2026-09-28 | Inhibrx Biosciences, Inc. | P | 3,000 | $101.7 | 740,548 | Form 4 |
| 2026-09-25 | Inhibrx Biosciences, Inc. | P | 3,324 | $98.87 | 733,872 | Form 4 |
| 2026-09-25 | Inhibrx Biosciences, Inc. | P | 2,176 | $99.6 | 736,048 | Form 4 |
| 2026-09-08 | Inhibrx Biosciences, Inc. | P | 500 | $108.24 | 719,648 | Form 4 |
| 2026-09-08 | Inhibrx Biosciences, Inc. | P | 9,681 | $112.28 | 730,548 | Form 4 |
| 2026-09-08 | Inhibrx Biosciences, Inc. | P | 1,219 | $111.88 | 720,867 | Form 4 |
| 2026-09-08 | Inhibrx Biosciences, Inc. | P | 5,895 | $99.29 | 711,443 | Form 4 |
| 2026-09-08 | Inhibrx Biosciences, Inc. | P | 6,605 | $100.64 | 718,048 | Form 4 |
| 2026-09-08 | Inhibrx Biosciences, Inc. | P | 1,100 | $107.12 | 719,148 | Form 4 |
Questions
What stock did Lappe Mark buy or sell?
Lappe Mark reported 10 non-derivative transactions on 2 SEC ownership filings in Q3 2026: 10 open-market purchases ($3.6M) and 0 sales, across 1 company.
Is Lappe Mark the same person as other filers with this name?
This page covers SEC CIK 1366074 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/lappe-mark-1366074.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.